<DOC>
	<DOCNO>NCT00976950</DOCNO>
	<brief_summary>The aim trial evaluate safety virological immunological efficacy Aptivus treatment-experienced patient advance HIV-1 infection develop resistance one protease inhibitor .</brief_summary>
	<brief_title>A Post Marketing Surveillance Study Assessing Long-term Efficacy Safety Aptivus Co-administered With Low-dose Ritonavir Treatment Experienced Patients With HIV-1 Infection Daily Clinical Practice .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Inclusion criterion : 1 . HIV1 infect patient treatment experience infected HIV1 strain resistant one protease inhibitor therapeutic option . 2 . The inclusion criterion follow criterion describe new SPC Exclusion criterion : The exclusion criterion follow criterion describe new SPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>